Struggling Regulus promotes former Lilly executive as new CMO

Deeg becomes CMO as other executives and staffers have left the building.

Under-pressure microRNA biotech Regulus has promoted Mark Deeg, M.D., Ph.D., into a new role as chief medical officer, just two months after he was named VP of translational medicine.

It’s not been good times at Regulus. After hemorrhaging executives this year, including its CEO and COO and a stripped-back workforce, things got worse yesterday when the biotech announced that AstraZeneca has handed back rights to a clinical-stage drug for NASH. Regulus will be dumping its ill-fated hepatitis C candidate RG-101 as well as another liver disease candidate, as it desperately tries to put its business back on secure footing.

What is left in the thinning pipeline for Deeg and chief R&D officer Timothy Wright? A revised phase 2 trial of RG-012 for kidney disease Alport syndrome, now its leading program, could deliver proof-of-concept data by the end of the year.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Following after is RGLS4326 for autosomal dominant polycystic kidney disease, but that is still in preclinical development with approval to start clinical trials not due until later this year.

Suggested Articles

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.